April 23, 2020 / 9:52 PM / a month ago

BRIEF-Edesa Biotech Says On April 17 Entered Into An Exclusive License Agreement With Novimmune SA

April 23 (Reuters) - Edesa Biotech Inc:

* EDESA BIOTECH SAYS ON APRIL 17 ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH NOVIMMUNE SA, - SEC FILING

* EDESA BIOTECH - OBTAINED EXCLUSIVE RIGHTS THROUGHOUT WORLD TO CERTAIN KNOW-HOW, PATENTS & DATA RELATING TO MONOCLONAL ANTIBODIES TARGETING TLR4 & CXCL10

* EDESA BIOTECH INC - TERM OF LICENSE AGREEMENT WILL REMAIN IN EFFECT FOR TWENTY-FIVE YEARS FROM DATE OF FIRST COMMERCIAL SALE OF LICENSED PRODUCTS

* EDESA BIOTECH INC - LICENSE AGREEMENT WILL AUTOMATICALLY RENEW FOR FIVE YEAR PERIODS

* EDESA BIOTECH INC - WILL PURCHASE FROM LIGHT CHAIN ITS INVENTORY OF TLR4 ANTIBODY FOR AN AGGREGATE PURCHASE PRICE OF $5.0 MILLION Source text: [bit.ly/2x0s5BM] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below